Sun Pharma sees 37.12% yoy decline in Q4 PAT to Rs399.84cr on logging exceptional items in the book

Q4 PAT was hampered due to an exceptional item of Rs260.44cr recorded by Sun Pharma.

May 27, 2020 04:05 IST India Infoline News Service

Sun Pharma
During the March 2020 (Q4FY20) quarter, Sun Pharma witnessed a 37.12% decline in its net profit to Rs399.84cr compared to Rs635.88cr in the corresponding period of the previous year. The company had posted a net profit of Rs913.52cr in Q3FY20.

Latest profit is below market sentiments, which is why the stock price became top underperformer on Sensex ending at Rs450.55 per piece down 1.85%.

Q4 PAT was hampered due to an exceptional item of Rs260.44cr recorded by Sun Pharma.

However, the company saw healthy business as its consolidated revenue rose by 14.67% to Rs8,078.03cr for the period compared to Rs7,044.26cr in Q4FY19.

For FY20, Sun Pharma's consolidated net profit and revenue stand at Rs3,764.93cr and Rs32,325.17cr respectively.

In its financial audit report, Sun Pharma said, "The Group continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics."

In its meeting held on Wednesday, the company's board recommended payment of a final dividend of Re1 per equity share for FY20 subject to shareholders approval at the ensuing Annual General Meeting. The dividend is expected to be paid during September 2020.

Related Story